Company Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.5 ^USD	+1.35%		0.00%	-22.28%

Apr. 23	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT
Apr. 23	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI

Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.

Number of employees: 19

Managers	Title	Age	Since
Anirvan Ghosh CEO	Chief Executive Officer	60	20-03-29
Nathaniel E. David FOU	Founder	56	09-03-29
Lynne Sullivan DFI	Director of Finance/CFO	58	20-07-31
Keith Leonard CHM	Chairman	62	15-12-31
Przemyslaw Sapieha CTO	Chief Tech/Sci/R&D Officer	-	21-01-31
Alexander Nguyen CNS	Consultant / Advisor	47	21-03-10

Members of the board	Title	Age	Since
Paul Berns BRD	Director/Board Member	57	18-03-26
Camille D. Samuels BRD	Director/Board Member	52	15-02-28
Keith Leonard CHM	Chairman	62	15-12-31
Nathaniel E. David FOU	Founder	56	09-03-29
Margo Roberts BRD	Director/Board Member	69	18-12-03
Anirvan Ghosh CEO	Chief Executive Officer	60	20-03-29
Gilmore O’Neill BRD	Director/Board Member	59	20-12-13
Michael Samar BRD	Director/Board Member	51	22-05-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,786,647	16,576,477 ( 98.75 %)	0	98.75 %

Name	Equities	%	Valuation
Alyeska Investment Group LP 6.204 %	1,041,331	6.204 %	2 M $
ARCH Venture Partners LLC 5.986 %	1,004,817	5.986 %	2 M $
Armistice Capital LLC 4.099 %	688,000	4.099 %	1 M $
Vanguard Group, Inc. (Subfiler) 3.346 %	561,602	3.346 %	921 027 $
Geode Capital Management LLC 0.7851 %	131,782	0.7851 %	216 122 $
Mayo Medical Ventures 0.7392 %	124,081	0.7392 %	203 493 $
BlackRock Institutional Trust Co. NA 0.6586 %	110,543	0.6586 %	181 291 $
UBS O'Connor LLC 0.5523 %	92,700	0.5523 %	152 028 $
Anirvan Ghosh 0.4691 %	78,746	0.4691 %	129 143 $
Nathaniel E. David 0.3511 %	58,939	0.3511 %	96 660 $

Unity Biotechnology, Inc.

285 East Grand Avenue

94080, South San Francisco

+650 416 1192

http://www.unitybiotechnology.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.5 USD

Average target price

6 USD

Spread / Average Target

+300.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
UNITY BIOTECHNOLOGY, INC.	-22.28%	25.18M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs